Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Bio-Techne (TECH) over the last 5 years, with Q2 2025 value amounting to $84.2 million.

  • Bio-Techne's Asset Writedowns and Impairment rose 42846.47% to $84.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $96.4 million, marking a year-over-year increase of 50551.33%. This contributed to the annual value of $80.5 million for FY2025, which is 26653.92% up from last year.
  • Per Bio-Techne's latest filing, its Asset Writedowns and Impairment stood at $84.2 million for Q2 2025, which was up 42846.47% from -$3.7 million recorded in Q1 2025.
  • In the past 5 years, Bio-Techne's Asset Writedowns and Impairment registered a high of $84.2 million during Q2 2025, and its lowest value of -$3.7 million during Q1 2025.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $15.9 million (2024), whereas its average is $23.0 million.
  • Over the last 5 years, Bio-Techne's Asset Writedowns and Impairment had its largest YoY gain of 42846.47% in 2025, and its largest YoY loss of 42846.47% in 2025.
  • Bio-Techne's Asset Writedowns and Impairment (Quarter) stood at $18.2 million in 2021, then fell by 12.35% to $15.9 million in 2024, then soared by 428.46% to $84.2 million in 2025.
  • Its Asset Writedowns and Impairment stands at $84.2 million for Q2 2025, versus -$3.7 million for Q1 2025 and $15.9 million for Q2 2024.